Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
0.4144
Dollar change
+0.0144
Percentage change
3.60
%
Index- P/E- EPS (ttm)-1.30 Insider Own42.62% Shs Outstand73.82M Perf Week6.26%
Market Cap30.70M Forward P/E- EPS next Y-1.06 Insider Trans1.02% Shs Float42.51M Perf Month-19.53%
Income-94.82M PEG- EPS next Q-0.34 Inst Own27.21% Short Float1.72% Perf Quarter2.30%
Sales2.91M P/S10.55 EPS this Y10.38% Inst Trans2.29% Short Ratio6.35 Perf Half Y17.10%
Book/sh2.42 P/B0.17 EPS next Y8.58% ROA-30.47% Short Interest0.73M Perf Year-60.53%
Cash/sh2.35 P/C0.18 EPS next 5Y11.10% ROE-43.17% 52W Range0.31 - 1.21 Perf YTD-9.93%
Dividend Est.- P/FCF- EPS past 5Y-64.52% ROI-38.46% 52W High-65.75% Beta1.43
Dividend TTM- Quick Ratio9.77 Sales past 5Y70.13% Gross Margin-267.30% 52W Low33.63% ATR (14)0.04
Dividend Ex-Date- Current Ratio10.51 EPS Y/Y TTM-1.99% Oper. Margin-3466.20% RSI (14)41.20 Volatility7.04% 7.91%
Employees265 Debt/Eq0.42 Sales Y/Y TTM280.52% Profit Margin-3257.30% Recom2.00 Target Price0.85
Option/ShortYes / Yes LT Debt/Eq0.38 EPS Q/Q-7.23% Payout- Rel Volume0.67 Prev Close0.40
Sales Surprise30.29% EPS Surprise-0.69% Sales Q/Q41.31% EarningsMar 18 AMC Avg Volume115.33K Price0.41
SMA20-8.58% SMA50-17.73% SMA200-16.68% Trades Volume77,808 Change3.60%
Date Action Analyst Rating Change Price Target Change
Aug-17-22Downgrade UBS Buy → Neutral $10 → $4.50
Aug-10-22Downgrade Goldman Buy → Neutral $3.50
Aug-10-22Downgrade BofA Securities Buy → Underperform $3
Jan-07-22Upgrade BofA Securities Neutral → Buy $21
Oct-15-21Resumed Cowen Outperform
Mar-20-24 10:10AM
Mar-19-24 06:19AM
Mar-18-24 04:24PM
04:05PM
Mar-04-24 04:05PM
10:55AM Loading…
Feb-05-24 10:55AM
10:54AM
Jan-07-24 05:00PM
Nov-15-23 11:43AM
10:47AM
Nov-14-23 04:06PM
04:01PM
Oct-24-23 04:22PM
Sep-20-23 11:28AM
Sep-08-23 08:00AM
12:27PM Loading…
Aug-10-23 12:27PM
Aug-09-23 04:46PM
04:01PM
Aug-08-23 04:05PM
Aug-02-23 04:05PM
Jul-26-23 04:05PM
Jun-01-23 04:05PM
May-11-23 06:38AM
May-10-23 09:45AM
May-09-23 04:21PM
04:01PM
Apr-25-23 04:05PM
Mar-06-23 05:51AM
Mar-03-23 07:30AM
Mar-02-23 04:22PM
04:01PM Loading…
04:01PM
Feb-23-23 04:05PM
Feb-16-23 04:05PM
Feb-06-23 07:00AM
07:00AM
Feb-02-23 08:00AM
Jan-25-23 05:05AM
Jan-09-23 06:00AM
Dec-21-22 04:05PM
Dec-15-22 05:14AM
Nov-28-22 05:11AM
Nov-07-22 04:01PM
Oct-24-22 04:05PM
Aug-25-22 04:05PM
Aug-18-22 04:05PM
Aug-14-22 10:49AM
Aug-10-22 05:00AM
Aug-09-22 04:01PM
Aug-08-22 04:30PM
Aug-02-22 07:30AM
Jul-28-22 04:06PM
04:05PM
Jun-20-22 10:22AM
Jun-07-22 08:00AM
Jun-06-22 04:05PM
Jun-03-22 08:00AM
May-21-22 08:00AM
May-10-22 04:05PM
04:01PM
07:30AM
May-05-22 08:40AM
Apr-26-22 04:15PM
Mar-07-22 12:54PM
10:38AM
Mar-02-22 11:30PM
04:05PM
Mar-01-22 08:00AM
Feb-28-22 07:30AM
07:30AM
07:30AM
Feb-23-22 04:15PM
Jan-18-22 10:11AM
Jan-10-22 07:30AM
07:30AM
07:30AM
07:30AM
07:30AM
Jan-07-22 08:00AM
Jan-06-22 04:05PM
07:30AM
Dec-27-21 11:38PM
Dec-16-21 07:30AM
Nov-29-21 10:17AM
Nov-11-21 05:30AM
Nov-09-21 04:05PM
Oct-28-21 04:05PM
Aug-27-21 10:38AM
Aug-05-21 07:30AM
Aug-03-21 06:05AM
Jun-22-21 10:16AM
Jun-01-21 04:05PM
May-26-21 11:56PM
Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer, David Barker and Andrew Spaventa in June 2016 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Spaventa AndrewChief Executive OfficerNov 17 '23Buy0.4275,00031,7554,061,206Nov 20 04:31 PM
Glezer Eli N.Chief Scientific OfficerNov 16 '23Buy0.43200,00085,6404,570,000Nov 20 04:30 PM
Spaventa AndrewChief Executive OfficerNov 16 '23Buy0.4143,46817,8573,986,206Nov 20 04:31 PM
Kamdar Kim P.DirectorAug 15 '23Sale0.53200,000106,9603,763,985Aug 15 07:17 PM
Kamdar Kim P.DirectorAug 14 '23Sale0.5777,99144,4243,963,985Aug 15 07:17 PM
Kamdar Kim P.DirectorAug 11 '23Sale0.60353,657210,6034,041,976Aug 15 07:17 PM
Glezer Eli N.Chief Scientific OfficerMay 17 '23Buy0.82170,000138,9244,355,000May 18 08:32 PM